Technology
Health
Pharmaceutical

Gritstone Oncology

$10.12
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-1.84%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell GRTS and other stocks, options, ETFs, and crypto commission-free!

About GRTS

Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.

Employees
113
Headquarters
Emeryville, California
Founded
2015
Market Cap
293.73M
Price-Earnings Ratio
Dividend Yield
Average Volume
149.79K
High Today
$10.66
Low Today
$10.01
Open Price
$10.16
Volume
75.27K
52 Week High
$32.90
52 Week Low
$8.75

Collections

Technology
Health
Pharmaceutical
Cancer Prevention
Medical
Biotechnology
2018 IPO
US

GRTS Earnings

-$7.60
-$5.26
-$2.93
-$0.59
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 12, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.